openPR Logo
Press release

Multiple Myeloma Market Set for Robust Growth Across the 7MM | DelveInsight

03-31-2025 02:56 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Multiple Myeloma Market Set for Robust Growth Across the 7MM |

Multiple Myeloma companies in the market include - Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie/Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., and others.

The multiple myeloma treatment paradigm is undergoing a dynamic evolution, marked by increasing therapeutic interventions by companies such as Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie/Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., and others.

DelveInsight's comprehensive report titled "Multiple Myeloma Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/multiple-myeloma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" offers an in-depth market analysis from 2020 to 2034. The analysis encompasses historical data, future projections of market size, detailed epidemiological trends, an assessment of the competitive landscape, and an evaluation of current and emerging therapeutic approaches.

According to DelveInsight's findings, the total Multiple Myeloma market size across the 7MM was USD 21.5 Billion in 2023. This market is anticipated to experience continued positive growth through 2034. The United States held the largest share of the 7MM market, accounting for USD 14.5 Billion in 2023. This highlights the significant market opportunity within the United States.

Download the Multiple Myeloma market report to understand which factors are driving the Multiple Myeloma therapeutic market @ Multiple Myeloma Market Trends [https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

The epidemiological landscape of Multiple Myeloma in the 7MM reveals that the total incidence of the disease was approximately 76K cases in 2024. This number is projected to rise over the coming years. Notably, the highest incidence of Multiple Myeloma is observed in individuals aged 65 years and above. Furthermore, the disease is more prevalent in men than in women, with over 50% of males in the United States diagnosed with multiple myeloma.

The DelveInsight report provides a comprehensive breakdown of this epidemiological data, including total incident cases of multiple myeloma, total symptomatic cases of multiple myeloma, gender-specific cases of multiple myeloma, age-specific cases of multiple myeloma, transplant-eligible cases of multiple myeloma, and treated patient pool across all lines of therapies.

Currently, the treatment landscape for Multiple Myeloma involves a variety of approaches, including chemotherapy, immunotherapy, targeted therapy, corticosteroids, and stem cell transplantation. Significant progress has been made with the development and approval of novel therapies such as immunomodulatory drugs (IMiDs), proteasome inhibitors, and monoclonal antibodies, which have improved patient outcomes. The treatment paradigm continues to evolve with the emergence of innovative strategies like CAR-T cell therapies and bispecific antibodies, offering new hope, particularly for patients with relapsed or refractory disease.

Discover evolving trends in the Multiple Myeloma treatment landscape @ Multiple Myeloma Therapeutics Market [https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Despite these significant advancements, challenges persist in the management of Multiple Myeloma, most notably the issue of disease relapse and the development of resistance to multiple drugs. The future treatment strategies are therefore focused on overcoming this resistance and achieving more durable responses. The developmental pipeline remains robust, with key pharmaceutical companies such as Regeneron (Linvoseltamab), Bristol Myers Squibb (Mezigdomide and Alnuctamab), AbbVie and Roche (VENCLEXTA), and Opna Bio (OPN-6602), among others, actively involved in bringing novel therapies to market.

Recent developments highlight ongoing innovation in multiple myeloma treatment. In February 2025, Opna Bio's OPN-6602 received FDA Orphan Drug designation for multiple myeloma, while in April 2024, the FDA approved Bristol-Myers Squibb and Bluebird Bio's ABECMA for the treatment of adult patients with relapsed or refractory multiple myeloma. These milestones, along with a robust pipeline of emerging therapies, continue to reshape the multiple myeloma treatment landscape, offering new hope for patients.

Unlock which Multiple Myeloma drug is expected to capture the largest market share in 7MM by 2032. Visit the Multiple Myeloma Market Insights [https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

In conclusion, the Multiple Myeloma market across the 7MM is poised for substantial growth in the coming years. This expansion is driven by a rising incidence of the disease, the increasing adoption of innovative therapies, and continuous efforts in research and development. While challenges such as relapse and drug resistance remain, the dynamic treatment landscape, marked by recent approvals and a promising pipeline, offers a positive outlook for the future of Multiple Myeloma management.

Table of Contents

1.

KEY INSIGHTS

2.

REPORT INTRODUCTION

3.

EXECUTIVE SUMMARY

4.

MULTIPLE MYELOMA MARKET OVERVIEW AT A GLANCE

5.

KEY EVENTS

6.

EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY

7.

MULTIPLE MYELOMA BACKGROUND AND OVERVIEW

8.

EPIDEMIOLOGY AND PATIENT POPULATION

9.

PATIENT JOURNEY

10.

KEY ENDPOINTS IN MULTIPLE MYELOMA

11.

MULTIPLE MYELOMA MARKETED DRUGS

12.

MULTIPLE MYELOMA EMERGING THERAPIES

13.

MULTIPLE MYELOMA: 7MM MARKET ANALYSIS

14.

MULTIPLE MYELOMA UNMET NEEDS

15.

SWOT ANALYSIS

16.

KOL VIEWS

17.

MARKET ACCESS AND REIMBURSEMENT

18.

APPENDIX

19.

DELVEINSIGHT CAPABILITIES

20.

DISCLAIMER

21.

ABOUT DELVEINSIGHT

Related Reports

Multiple Myeloma Pipeline Insight [https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Multiple Myeloma Pipeline Insight provides comprehensive insights about the Multiple Myeloma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Multiple Myeloma companies, including CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co. Ltd., GPCR Therapeutics, and Chimerix among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=multiple-myeloma-market-set-for-robust-growth-across-the-7mm-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Multiple Myeloma Market Set for Robust Growth Across the 7MM | DelveInsight here

News-ID: 3947578 • Views:

More Releases from ABNewswire

Procolored Announces 2025 Black Friday & Cyber Monday Deals Across DTF and UV Printer Lineup
Procolored Announces 2025 Black Friday & Cyber Monday Deals Across DTF and UV Pr …
Industry-leading print manufacturer unveils limited-time offers, bundles, and loyalty rewards for U.S. customers. Shenzhen - Today, Procolored [https://www.procolored.com/], global manufacturer of DTF, UV DTF, and UV printers, announced its 2025 Black Friday and Cyber Monday sale event, featuring deep discounts, bundles, and loyalty rewards across its product lineup. The promotional period spans November 1 to December 7, 2025, with exclusive offers available to U.S. customers through Procolored.com and Amazon. Black Friday Season
Mobility Indy's Donation Helps Create Lasting Memory for Family Facing Cancer
Mobility Indy's Donation Helps Create Lasting Memory for Family Facing Cancer
Mobility Indy provided a free scooter rental for a young mother battling cancer, enabling a cherished family outing at the Children's Museum. INDIANAPOLIS, IN - October 31, 2025 - Mobility Indy [https://mobilityindy.com/], a local provider of mobility solutions, partnered with the nonprofit organization One Day to Remember [https://www.onedaytoremember.org/] to provide a free scooter rental [https://mobilityindy.com/rentals/mobility-scooters/] and personal delivery for a young mother battling metastatic lung cancer, allowing her to enjoy a
Ceramic Matrix Composites Market Future Demand, Revenue Forecast, and Strategic Growth Outlook 2025-2030
Ceramic Matrix Composites Market Future Demand, Revenue Forecast, and Strategic …
The Ceramic Matrix Composites (CMCs) Market is witnessing strong growth, fueled by rising demand from aerospace, defense, and energy industries for lightweight, high-strength, and heat-resistant materials. Key players such as GE Aviation, Rolls-Royce, SGL Carbon, CoorsTek, and Lancer Systems are focusing on material innovation, production efficiency, and strategic collaborations to enhance performance and sustainability in high-temperature applications. The ceramic matrix composite market is projected to reach USD 20.83 billion by 2030
Playout Automation & Channel-in-a-box Market Leading Companies, Future Opportunities, Strategies, and Regional Insights
Playout Automation & Channel-in-a-box Market Leading Companies, Future Opportuni …
Playout Automation & Channel-in-a-Box Market by Solution (Playout Scheduling & Management, Master Control Automation, Media Asset and Content Management, Graphics and Branding), Channel Type (Single, Multiple), Coverage Area - Global Forecast to 2028. The playout automation and channel-in-a-box market [https://www.marketsandmarkets.com/Market-Reports/channel-in-a-box-it-based-playout-market-783.html?utm_campaign=channelinaboxitbasedplayoutmarket&utm_source=abnewswire.com&utm_medium=referral] is expected to grow at a compound annual growth rate (CAGR) of 15.8% over the course of the forecast period, from an anticipated USD 2.9 billion in 2023 to USD 6.1

All 5 Releases


More Releases for Bio

Human Plasma Products Market 2023: Industry Future Trends | Takeda, CSL, Grifols …
The Human Plasma Products market research report is proficient and top to bottom research by specialists on the current state of the industry. This statistical surveying report gives the most up to date industry information and industry future patterns, enabling you to distinguish the items and end clients driving income development and benefit. It centres around the real drivers and restrictions for the key players and present challenge status with
Gene Therapy Products Market | Advantagene, Avalanche Bio, Bluebird Bio, Cellado …
The global gene therapy products market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the gene therapy products market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
Bio-based Polymethyl Methacrylate (Bio-PMMA) Market 2023 | Detailed Report
The Bio-based Polymethyl Methacrylate (Bio-PMMA) report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research. The Bio-based Polymethyl Methacrylate (Bio-PMMA) research report
Bio Pharma Buffer Market – A comprehensive study by Key Players: Bio-Rad, Lonz …
Latest Market intelligence report released by HTF MI with title "COVID-19 Outbreak-Global Bio Pharma Buffer Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020" is designed covering micro level of analysis by manufacturers and key business segments. The COVID-19 Outbreak-Global Bio Pharma Buffer Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary
IVIG Market Anticipated a Noteworthy CAGR during 2019-2024 & Companies Included …
A report added to the rich database of Qurate Business Intelligence, titled “World IVIG Market by Product Type, Players and Regions - Forecast to 2024”, provides a 360-degree overview of the Global market. Approximations associated with the market values over the forecast period are based on empirical research and data collected through both primary and secondary sources. The authentic processes followed to exhibit various aspects of the market makes the
Green & Bio-based Solvents Market Analysis, Demand, & Opportunities till 2023 | …
A latest research report titled as “Green & Bio-based Solvents Market for Paints & Coatings, Printing Inks, Commercial & Domestic Cleaning, Adhesives & Sealants, Pharmaceutical, Cosmetics, and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023” has been recently added to the vast portfolio of Market Research Reports Search Engine (MRRSE) online research offerings. This report is a professional and in-depth analysis on the